Similarly, ErbB3 has been shown to be an important factor in resistance and metastasis development29, 56, and can be seen to be upregulated in patient 3 and 6 who showed tumour progression while on treatment (Supplementary Figs. 28, 31). Here, ERBB3 is linked to neoplasm.